Imatinib mesylate induction of ROS-dependent apoptosis in melanoma B16F0 cells

Journal of Dermatological Science

Volumn 62, Issue 3, 2011, Pages 183-191

  Chang, Shao Ping ^a,b,c   Shen, Shing Chuan ^a   Lee, Woan Rouh ^a,d   Yang, Ling Ling ^e   Chen, Yen Chou ^a,f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; Imatinib mesylate (STI571); MAPKs; Melanoma cells; Reactive oxygen species

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; CASPASE 9; IMATINIB; REACTIVE OXYGEN METABOLITE; SB 600125; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN B16F0; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION;

ANIMALS; ANTHRACENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; FLAVONOIDS; FLOW CYTOMETRY; IMIDAZOLES; MELANOMA, EXPERIMENTAL; MEMBRANE POTENTIALS; MICE; MITOCHONDRIA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; REACTIVE OXYGEN SPECIES;

EID: 79955902721     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.03.001     Document Type: Article

References (39)

1. Cohen C., Zavala-Pompa A., Sequeira J.H., Shoji M., Sexton D.G., Cotsonis G., et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res 2002, 8:3728-3733.
2. Meier F., Busch S., Lasithiotakis K., Kulms D., Garbe C., Maczey E., et al. Combined targeting of MAPK and AKT signaling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007, 156:1204-1213.
3. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006, 5:1136-1144.
4. Hu W.P., Yu H.S., Sung P.J., Tsai F.Y., Shen Y.K., Chang L.S., et al. DC-81-indole conjugate agent induces mitochondria mediated apoptosis in human melanoma A375 cells. Chem Res Toxicol 2007, 20:905-912.
5. Doudican N., Rodriguez A., Osman I., Orlow S.J. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res 2008, 8:1308-1315.
6. Yang J., Liu X., Bhalla K., Kim C.N., Ibrado A.M., Cai J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997, 275(5303):1129-1132.
7. Chandra J., Hackbarth J., Le S., Loegering D., Bone N., Bruzek L.M., et al. Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells. Blood 2003, 102:4512-4519.
8. Hervouet E., Simonnet H., Godinot C. Mitochondria and reactive oxygen species in renal cancer. Biochemistry 2007, 89:1080-1088.
9. Galluzzi L., Larochette N., Zamzami N., Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
10. Yi-Fen Wang Y.F., Chen C.Y., Chung S.F., Chiou Y.H., Lo H.R. Involvement of oxidative stress and caspase activation in paclitaxel-induced apoptosis of primary effusion lymphoma cells. Cancer Chemother Pharmacol 2004, 54:322-330.
11. Bragado P., Armesilla A., Silva A., Porras A. Apoptosis by cisplatin requires p53 mediated p38 alpha MAPK activation through ROS generation. Apoptosis 2007, 12:1733-1742.
12. Tsang W.P., Chau S.P.Y., Kong S.K., Fung K.P., Kwok T.T. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 2003, 73:2047-2058.
13. Wu W.S., Wu J.R., Hu C.T. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev 2008, 27:303-314.
14. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002, 192:1-15.
15. Meyskens F.L., Farmer P., Fruehauf J.P. Redox regulation in human melanocytes and melanoma. Pigment Cell Res 2001, 14:148-154.
16. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J Pharm Exp Ther 2000, 295:139-145.
17. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000, 289:1938-1942.
18. David A., Tuveson D.A., Willis N.A., Jacks T., Griffin J.D., Singer S., et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001, 20:5054-5058.
19. Taira Maekawa T., Eishi Ashihara E., Kimura S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 2007, 12:327-340.
20. Ogawa Y., Kawamura T., Furuhashi M., Tsukamoto K., Shimada S. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate. J Dermatol Sci 2008, 51:190-199.
21. Uziel O., Fenig E., Nordenberg J., Beery E., Reshef H., Sandbank J., et al. Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 2005, 92:1881-1891.
22. Chow J.M., Lin H.Y., Shen S.C., Wu M.S., Lin C.W., et al. Zinc protoporphyrin inhibition of lipopolysaccharide-, lipoteichoic acid-, and peptidoglycan-induced nitric oxide production through stimulating iNOS protein ubiquitination. Toxciol Appl Pharmacol 2009, 237:357-365.
23. Gordon P.M., David E., Fisher D.E. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line. J Biol Chem 2010, 285:14109-14114.
24. Biswas S.K., Zhao Y., Sandirasegarane L. Imatinib induces apoptosis by inhibiting PDGF- but not insulin-induced PI 3-kinase/Akt survival signaling in RGC-5 retinal ganglion cells. Mol Vision 2009, 15:1599-1610.
25. Ranza E., Mazzini G., Facoetti A., Nano R. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neuro-Oncol 2010, 96:349-357.
26. Wittgen H.G.M., van Kempen L.C.L.T. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007, 17:400-409.
27. Dunning S., Hannivoort R.A., de Boer J.F., Buist-Homan M., Faber K.N., Moshage H. Superoxide anions and hydrogen peroxide inhibit proliferation of activated rat stellate cells and induce different modes of cell death. Liver Int 2009, 29:922-932.
28. Straface E., Vona R., Ascione B., Matarrese P., Strudthoff T., Franconi F., et al. Single exposure of human fibroblasts (WI-38) to a sub-cytotoxic dose of UVB induces premature senescence. FEBS 2007, 581:4342-4348.
29. Placzek M., Bprzybilla B., Kerkmann U., Gaube S., Gilbertz K.P. Effect of ultraviolet (UV) A, UVB or ionizing radiation on the cell cycle of human melanoma cells. Br J Dermatol 2007, 156:843-847.
30. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009, 9:537-549.
31. Hocker T.L., Singh M.K., Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J Invest Dermatol 2008, 128:2575-2595.
32. Liu J., Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005, 15:36-42.
33. Zarubin T., Han J.H. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005, 15:11-18.
34. Alexaki V.-I., Javelaud D., Mauviel A. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 2008, 21:429-438.
35. Tsuchiya T., Tsuno N.H., Asakage M., Yamada J., Yoneyama S., Okaji Y., et al. Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells. Hepato-Gastroenterol 2008, 55:930-935.
36. Deininger Michel W.N., Druker B.J. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003, 55:401-423.
37. Yasuda A., Sawai H., Takahashi H., Ochi N., Matsuo Y., Funahashi H., et al. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer 2006, 5:46-56.
38. Kumar S., Mishra N., Raina D., Saxena S., Kufe D. Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571. Mol Pharmacol 2003, 63:276-282.
39. Yu C., Krystal G., Varticovksi L., McKinstry R., Rahmani M., Dent P., et al. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 2002, 62. 188-99.